Omeros Corporation - Common Stock (NQ:OMER)

18.61 +0.14 (+0.76%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Omeros Corporation - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Nasdaq Down Over 100 Points; Tyson Foods Posts Downbeat Earnings ↗

February 06, 2023

U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dropping over 80 points on Monday. The Dow traded down 0.15% to 33,875.74 while the NASDAQ fell 0.88% to 11,900.97. The S&P...

Via Benzinga

Why Omeros Are Trading Higher By 32%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

February 06, 2023

Gainers Secoo Holding Limited (NASDAQ: SECO) jumped 156% to $4.3600. Arqit Quantum Inc. (NASDAQ: ARQQ) gained 41.5% to $3.54.

Via Benzinga

Crude Oil Down Over 1%; Nasdaq Drops 80 Points ↗

February 06, 2023

U.S. stocks traded lower midway through trading, with the Nasdaq Composite dropping over 80 points on Monday. The Dow traded down 0.21% to 33,853.11 while the NASDAQ fell 0.60% to 11,934.76. The S&P...

Via Benzinga

Why Omeros Corporation Stock Is Skyrocketing Today ↗

February 06, 2023

The Omeros will now be able to fund operations at least through 2025.

Via The Motley Fool

UBS Downgrades Omeros: Here's What You Need To Know ↗

December 08, 2022

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

February 06, 2023

Via Benzinga

Omeros Corporation Receives $200 Million Milestone Payment from Rayner Surgical

February 06, 2023

From Omeros Corporation

Via Business Wire

12 Health Care Stocks Moving In Friday's After-Market Session ↗

December 23, 2022

Via Benzinga

Why Applied Molecular Transport Shares Are Trading Lower By Over 55%? Here Are 47 Stocks Moving In Friday's Mid-Day Session ↗

December 23, 2022

Gainers

Via Benzinga

US Stocks Open Lower; Dow Falls Over 100 Points ↗

December 23, 2022

U.S. stocks traded lower this morning, with the Dow Jones dropping over 100 points on Friday.

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

December 22, 2022

Via Benzinga

Why Canoo Shares Are Trading Higher By Over 12%? Here Are 32 Stocks Moving In Friday's Mid-Day Session ↗

November 25, 2022

Gainers Peak Bio, Inc. (NYSE: PKBO) shares jumped 49.1% to $7.08.

Via Benzinga

US Stocks Mixed On Black Friday; Dow Rises Over 100 Points ↗

November 25, 2022

U.S. stocks traded mixed this morning, with the Dow Jones gaining more than 100 points on Friday. Equity markets will close early on Black Friday, the day after Thanksgiving.

Via Benzinga

Omeros Corporation Reports Third Quarter 2022 Financial Results

November 09, 2022

From Omeros Corporation

Via Business Wire

Preview: Omeros's Earnings ↗

November 08, 2022

Omeros (NASDAQ:OMER) is set to give its latest quarterly earnings report on Wednesday, 2022-11-09. Here's what investors need to know before the announcement. Analysts estimate that Omeros will report...

Via Benzinga

Omeros Corporation Receives Decision from FDA on Formal Dispute Resolution Request for Narsoplimab

November 08, 2022

From Omeros Corporation

Via Business Wire

Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2022

November 04, 2022

From Omeros Corporation

Via Business Wire

Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting

November 03, 2022

From Omeros Corporation

Via Business Wire

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

October 25, 2022

Gainers DBV Technologies (NASDAQ:DBVT) stock increased by 18.7% to $1.9 during Tuesday's after-market session. The company's market cap stands at $356.7 million.

Via Benzinga

Peering Into Omeros's Recent Short Interest ↗

October 03, 2022

Omeros's (NASDAQ:OMER) short percent of float has fallen 4.78% since its last report. The company recently reported that it has 9.48 million shares sold short, which is 15.75% of all regular shares...

Via Benzinga

Omeros Corporation Announces Royalty Monetization Transaction with DRI Healthcare Trust

October 03, 2022

From Omeros Corporation

Via Business Wire

Why ZW Data Action Technologies Jumped 37%; Here Are 71 Biggest Movers From Yesterday ↗

September 16, 2022

Gainers

Via Benzinga

Important Biotech Catalysts For September 15, 2022 - End Of The Day Summary ↗

September 15, 2022

Via Benzinga

Analyzing Omeros's Short Interest ↗

September 15, 2022

Omeros's (NASDAQ:OMER) short percent of float has fallen 3.78% since its last report. The company recently reported that it has 9.96 million shares sold short, which is 16.54...

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

September 15, 2022

Via Benzinga

Why Adobe Is Trading Lower By 17%, Here Are 49 Stocks Moving In Thursday's Mid-Day Session ↗

September 15, 2022

Gainers HeartBeam, Inc. (NASDAQ: BEAT) shares surged 58% to $1.96 after the company announced its patent for a 12-lead electrocardiogram patch monitor intended for detection of acute coronary syndrome...

Via Benzinga

Omeros COVID-19 Treatment Reduced Mortality Risk, But Biased Data Rendered Analysis Meaningless ↗

September 15, 2022

Via Benzinga

US Stocks Gain Following Economic Data; Dow Jumps Over 100 Points ↗

September 15, 2022

U.S. stocks traded higher this morning, following the release of several economic reports.

Via Benzinga

Omeros Corporation Reports Narsoplimab Treatment Results in Critically Ill COVID-19 Patients in I-SPY COVID Trial

September 15, 2022

From Omeros Corporation

Via Business Wire

I-SPY COVID Trial Sponsored by Quantum Leap Healthcare Collaborative Reports Assessment of Narsoplimab for Treatment of Critically Ill Patients With COVID-19

September 15, 2022

From Quantum Leap Healthcare Collaborative and Omeros Corporation

Via Business Wire

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.